Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin Apotheke
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
Wiener klinische Wochenschrift
Erschienen in: Wiener klinische Wochenschrift 15-16/2013

01.08.2013 | review

Benefits and pitfalls of cardiovascular medication in seniors

verfasst von: Hana Matejovska Kubesova, PhD, Prof. Pavel Weber, MD PhD, Hana Meluzinova, MD, Katarina Bielakova, MD, Jan Matejovsky, PhD

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2013

Einloggen, um Zugang zu erhalten

Summary

Authors analyze actual situation in treatment of cardiovascular diseases in older patients. Different groups of recommended drugs are discussed separately; possible risks for elderly patients are stressed. Angiotensin converting enzyme inhibitors—this group is widely used in older patients because of their hypotensive effect, positive influence on cardiac failure, and positive modulation of endothelial dysfunction. The risk of hyperkalemia must be considered. Antiaggregants and anticoagulants are proved as potent prophylactic treatment, but the associated risk of gastrointestinal bleeding must be weighed very carefully. Bradycardia related to β-blockers, especially in combination with other medications lowering the heart rate must be taken into account. Otherwise, this group brings the highest profit in cardiovascular diseases as for morbidity and mortality. Attention is paid to calcium channel blockers, statins, diuretics, nitrates, and digoxin. A table listing the possible side effects and clinical symptoms of overdose by medications most frequently used in the elderly concludes the article.
Nächster Artikel Coronary subclavian steal syndrome: an extracoronary cause of acute coronary syndrome
Literatur
1.
Kalvach Z, Zadak Z, Jirak R, et al. Geriatrics a gerontology. Praha: Grada publishing a.s.; 2004 (ISBN 80-247-0548-6).
2.
Topinkova E. Geriatrics for practice. 1. vyd. Praha: Galen; 2005. S. 270.
3.
Fialova D, Topinkova E, Gambassi G, et al. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA. 2005;293(11):1348–58.PubMedCrossRef
4.
Kubesova H, Holik J, Bogrova I, et al. The influence of new scientific information on the treatment of elderly patients in general practice. Acta Medica Austriaca, od 2001;52–6, (5 s. ISSN 0303-8173).
5.
Kubesova H, Holik J, Weber P, et al. Drug consumption and risks of polypharmacotherapy in seniors. Cas Lek Ces. 2006;9:708–12.
6.
Zed PJ, Abu-Laban RJ, Balen RM. Incidence, severity and preventability of medication-related visits to emergency department: a prospective study. CMAJ. 2008;178(12):1563–9.PubMedCrossRef
7.
Beers MH, Ouslander JG, Rollingher I, Reuben DB, Brooks J, Beck J. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. 1991;151:1825–32.PubMedCrossRef
8.
Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly: an update. Arch Intern Med. 1997;157:1531–6.PubMedCrossRef
9.
Mann E, Böhmdorfer B, Frühwald T, et al. Potentially inappropriate medication in geriatric patients: the Austrian consensus panel list. Wien Klin Wochenschr. 2012 Mar;124(5–6):160–9 (Epub 2011 Dec 2).PubMedCrossRef
10.
Kubesova H, Weber P, Kala P, et al. Acute coronary syndrome in seniors. Ces Ger Rev. 2008;6(3):41–6.
11.
Matejovsky J. Complex evaluation of czech seniors living in their own environment. Diploma thesis, Faculty of st. Agnes, Bratislava, Slovakia, 2007, 107p.
12.
Hemmelgarn BR, Chen G, Walker R, et al. Trends in antihypertensive drug prescriptions and physician visits between 1996 and 2006. Can J Cardiol. 2008;24(6):507–12.PubMedCrossRef
13.
Blakley BW, Gulati H. Identifying drugs that cause dizziness. J Otolaryngol. 2008;37(1):11–5.
14.
Konopa J, Bullo B, Rutkowski B. Life threatening drug-induced hyperkalemia—case report. Pol Arch Med Wewm. 2006;115(3):238–42.
15.
16.
Pilote L, Abrahamovicz M, Eisenberg M, et al. Effect of different angiotensin-converting enzyme inhibitors on mortality among elderly patients with congestive heart failure. CMAJ. 2008;178(10):1303–11.PubMedCrossRef
17.
Masunari N, Fujiwara S, Nakata Y, et al. Effect of angiotensin converting enzyme inhibitor and benzodiazepine intake on bone loss in older Japanese. Hiroshima J Med Sci. 2008;57(1):17–25.PubMed
18.
Flammer AJ, Sudano I, Hermann F, et al. Angiotensin converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation. 2008;117(17):2262–9.PubMedCrossRef
19.
Werner C, Baumruckel M, Teo KK, et al. RAS blockade with ARB and ACE inhibitors: current perspective on rationale and patients selection. Clin Res Cardiol. 2008;5:305–11.
20.
Recommendation of Czech cardiology association for diagnostics and treatment of cardiac failure. Cor et Vasa. 2007;49(1):K5–34 (Suppl. Cor Vasa 2007;49(11):75–104).
21.
Tadevosyan A, Maclaughlin EJ, Karamyan VT. Angiotensin II type 1 receptor antagonists in the treatment of hypertension in elderly patients: focus on patient outcomes. Patient Relat Outcome Meas. 2011 Jul;2:27–39 (Epub 2011 Jan 25).PubMed
22.
Toyama T, Sato C, Koyama K. Olmesartan improves coronary flow reserve of hypertensive patients using coronary magnetic resonance imaging compared with amlodipine. Cardiology. 2012;122(4):230–6 (Epub 2012 Aug 14).PubMedCrossRef
23.
Matsui T, Yamagishi S, Takeuchi M. Irbesartan inhibits advanced glycation end product (AGE)-induced proximal tubular cell injury in vitro by suppressing receptor for AGEs (RAGE) expression. Pharmacol Res. 2010 Jan;61(1):34–9 (Epub 2009 Jul 25).PubMedCrossRef
24.
Kahn R, Robertson RM, Smith R, et al. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008;118(7):218–22.
25.
Vekasi J, Koltai K, Gaal V, et al. The effect of aspirin on hemorheological parameters of patients with diabetic retinopathy. Clin Hemorheol Microcirc. 2008;39(1–4):385–9.PubMed
26.
27.
Juby AG, Davis P. Utility of published guidelines on the use of nonsteroidal anti-inflammatory drugs in the elderly. Clin Rheumatol. 2008;27(7):835–42.
28.
29.
Nagata Y, Inomata JI, Kinoshita M. Impact of proton pump inhibitors or famotidine on the antiplatelet actions during dual-antiplatelet therapy in Japanese patients. Cardiovasc Interv Ther. 2012 Aug 11 (Epub ahead of print).
30.
Jaspers Focks J, Brouwer MA, Oijen MG van. Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review. Heart. 2013;99(8):520–7.
31.
Macaione F, Montaina C, Evola S. Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent implantation. ISRN Cardiol. 2012;2012:692761 (Epub 2012 Jun 27).PubMed
32.
33.
Arvanitakis Z, Grodstein F, Bienias JL, et al. Relation of NSAIDs to incident, change in cognitive function and AD patology. Neurology. 2008;70(23):2219–25.PubMedCrossRef
34.
Szekely CA, Green RC, Breitner JC, et al. No advantage of A beta 42-lowering NSAIDs for prevention of Alzheimer dementia in six pooled cohort studies. Neurology. 2008;70(24):2291–8.PubMedCrossRef
35.
Cleland JG, Coletta AP, Yassin A, et al. Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT. Eur J Heart Fail. 2009 Dec;11(12):1214–9.PubMedCrossRef
36.
Vojacek J. Results of RE-LY study promise more effective, simplier and safer prevention of embolic complications in patients with non valvular atrial fibrillation. Vnitr Lek. 2010;55(11):1085–8.
37.
Weltermann A, Brodmann M, Domanovits H, et al. Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management. Wien Klin Wochenschr. 2012 May;124(9–10):340–7 (Epub 2012 May 11).PubMedCrossRef
38.
Gallagher A, Ritbrock S, Plomb J, et al. Initiation and persistence of warfarin or aspirin in patients with chronic atrial fibrillation in general practice: do the appropriate patients receive stroke prophylaxis? J Throm Hemost. 2008;6:913–9.CrossRef
39.
Guidelines for the management of atrial fibrillation. ESC guidelines. Eur Heart J. 2010;31:2369–429.CrossRef
40.
Onalan O, Cumurcu BE, Bekar L, et al. Complete atrioventricular block associated with concomitant use of metoprolol and paroxetine. Mayo Clin Proc. 2008;83(5):595–9.PubMed
41.
Astrolm-Lilja C, Odeberg JM, Ekman E, et al. Drug-induces torsades de pointes: a review of the Swedish pharmacovigilance database. Pharmacoepidemiol Drug Saf. 2008;17(6):587–92.CrossRef
42.
Galinier M, Emeriau JP. Prescribing Beta-blockers in elderly patients with heart failure. Presse Med. 2008;37(6 Pt 2):1047–54.PubMedCrossRef
43.
Cleland JGF, Coletta AP, Torabi A, Clark AL. Clinical trials update from the European Society of Cardiology heart failure meeting 2009: CHANCE, B-Convinced, CHAT, CIBIS-ELD and Signal HF. Eur J Heart Fail. 2009;11(8):802–5.PubMedCrossRef
44.
Rector TS, Nand IS, Nelson DB, et al. Carvedilol versus controlled-release metoprolol for elderly veterans with heart failure. J Am Geriatr Soc. 2008;56(6):1021–7.PubMedCrossRef
45.
46.
Schindler K, Schima W, Kaliman JF. Cryptogenic organizing pneumonia due to amiodarone: long-term follow-up after corticosteroid treatment. Wien Klin Wochenschr. 2010 Aug;122(15–16):511–4 (Epub 2010 Aug 2).PubMedCrossRef
47.
Zgazarova S, Jedlickova H, Vasku V. Unwanted skin effects of amiodaron. Vnitr Lek. 2009;55(10):976–80.PubMed
48.
49.
De Ferrari GM, Dusi V. Drug safety evaluation of dronedarone in atrial fibrillation. Expert Opin Drug Saf. 2012;11(6):1023–45.PubMedCrossRef
50.
Said SM, Esperer HD, Kluba K, et al. Efficacy and safety profile of dronedarone in clinical practice. Results of the Magdeburg Dronedarone Registry (MADRE study). Int J Cardiol. 2012 Jul 9 (Epub ahead of print).
51.
Manderbacka K, Keskimaki I, Reunanen A, et al. Equity in the use of antithrombotic drugs, beta-blockers and statins among Finnish coronary patients. Int J Equity Health. 2008;7(1):16–20.PubMedCrossRef
52.
Pretnar-Oblak J, Sebestjan M, Sabovic M. Statin treatment improves cerebral more than systemic endothelial dysfunction in patiens with arterial hypertension. Am J Hypertens. 2008;21(6):674–8.PubMedCrossRef
53.
Foody JM, Joyce AT, Rudolph AE, et al. Persistence of atorvastatin and simvastatin in patients with and without prior cardiovasculat diseases: a US managed care study. Curr Med Res Opin. 2008;24(7):1987–2000.PubMedCrossRef
54.
Pella D. Statin myopathy – rarity or reality? Vnitr Lek. 2010;9:853–7.
55.
Föger B, Patsch JR. LDL-cholesterol in secondary prevention: goal-attainment in patients on lipid-lowering drugs in private practice and in hospitals in Austria (ZIEL). Wien Klin Wochenschr. 2011 Jan;123(1–2):21–7 (Epub 2010 Dec 20).PubMedCrossRef
56.
Drexel H, Chazelle F, Fauer C, et al. Persistent dyslipidemia in Austrian patients treated with statins for primary and secondary prevention of atherosclerotic events – Results of the DY Slipidemia International Study (DYSIS). Wien Klin Wochenschr. 2011 Oct;123(19–20):611–7 (Epub 2011 Sep 29).PubMedCrossRef
57.
Pregelj P. Involvement of cholesterol in the pathogenesis of Alzheimer’s disease: Role of statins. Psychiatr Danub. 2008;20(2):162–7.PubMed
58.
Duron E, Hanon O. Vascular risk factors, cognitive decline and dementia. Vascular Health Risk Manag. 2008;4(2):363–81.
59.
Kevelaitiene S, Slapikas R. A new approach to the treatment of dyslipidemia. Medicina (Kaunas). 2008; 44(5):407–13.
60.
Goldstein MR, Mscitelli L, Pezzeta F. The double-edged sword of statin immunomodulation. Int J Cardiol. 2008;5:432–36.
61.
Hirooka Y, Komara Y, Sagara Y, et al. Effects of valsartan or amlodipine on endothelial function and oxidative stress after one year follow-up in patients with essential hypertension. Clin Exp Hypertens. 2008;30(3):267–76.PubMedCrossRef
62.
63.
64.
Kudoh T, Nagawaga T, Nawaga I. Additional small amounts of diuretics improve blood pressure control at low cost without disadvantages in blood sugar metabolism. Hypertens Res. 2008;31(3):455–62.PubMedCrossRef
65.
Spinar J, Soucek M. Rewieved recommendations for diagnostics and treatment of hypertension. Vnitr Lek. 2010;56(2):157–61.PubMed
66.
67.
Oelze M, Knorr M, Kröller-Schön S, et al. Chronic therapy with isosorbide-5-mononitrate causes endothelial dysfunction, oxidative stress, and a marked increase in vascular endothelin-1 expression. Eur Heart J. 2012 May 3 (Epub ahead of print).
68.
69.
Metadaten
Titel
Benefits and pitfalls of cardiovascular medication in seniors
verfasst von
Hana Matejovska Kubesova, PhD
Prof. Pavel Weber, MD PhD
Hana Meluzinova, MD
Katarina Bielakova, MD
Jan Matejovsky, PhD
Publikationsdatum
01.08.2013
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2013
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-013-0395-2

Weitere Artikel der Ausgabe 15-16/2013

Wiener klinische Wochenschrift 15-16/2013 Zur Ausgabe

mitteilungen der gesellschaft der ärzte in wien

Preisverleihung

original article

Temozolomide added to whole brain radiotherapy in patients with multiple brain metastases of non-small-cell lung cancer: a multicentric Austrian phase II study

mitteilungen der österreichischen gesellschaft für innere medizin

Die Österreichische Palliativgesellschaft (OPG)

original article

A new model using platelet indices to predict liver fibrosis in patients with chronic hepatitis B infection

nachruf

Nachruf Prof. Dr. Walter H. Hörl 11.7.1945 – 25.6.2013

case report

A rare cause of acute coronary syndrome: electrical shock